
Khaitan Chemicals (KHAICHEM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
1.6B
Gross Profit
487.8M
30.36%
Operating Income
81.7M
5.08%
Net Income
86.3M
5.37%
Balance Sheet Metrics
Total Assets
6.2B
Total Liabilities
4.0B
Shareholders Equity
2.2B
Debt to Equity
1.78
Cash Flow Metrics
Revenue & Profitability Trend
Khaitan Chemicals Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 7.2B | 5.3B | 8.9B | 8.2B | 4.8B |
Cost of Goods Sold | 5.1B | 4.6B | 6.7B | 5.7B | 3.2B |
Gross Profit | 2.1B | 718.5M | 2.2B | 2.6B | 1.6B |
Gross Margin % | 29.5% | 13.4% | 24.5% | 31.4% | 33.7% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 568.7M | 25.7M | 24.4M | 28.5M | 22.7M |
Other Operating Expenses | 1.1B | 638.7M | 981.8M | 917.9M | 689.7M |
Total Operating Expenses | 1.6B | 664.4M | 1.0B | 946.4M | 712.4M |
Operating Income | 124.5M | -400.0M | 725.6M | 1.2B | 571.0M |
Operating Margin % | 1.7% | -7.5% | 8.2% | 15.1% | 11.9% |
Non-Operating Items | |||||
Interest Income | - | 9.9M | 8.6M | 5.6M | 4.8M |
Interest Expense | 298.1M | 284.1M | 166.1M | 109.9M | 120.9M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -165.0M | -718.6M | 510.3M | 1.0B | 417.7M |
Income Tax | -179.0M | -13.7M | 136.7M | 227.2M | 148.2M |
Effective Tax Rate % | 0.0% | 0.0% | 26.8% | 22.1% | 35.5% |
Net Income | 14.0M | -704.9M | 421.3M | 795.0M | 248.7M |
Net Margin % | 0.2% | -13.2% | 4.8% | 9.7% | 5.2% |
Key Metrics | |||||
EBITDA | 239.2M | -319.3M | 771.4M | 1.3B | 636.5M |
EPS (Basic) | ₹0.14 | ₹-7.27 | ₹4.34 | ₹8.20 | ₹2.56 |
EPS (Diluted) | ₹0.14 | ₹-7.27 | ₹4.34 | ₹8.20 | ₹2.56 |
Basic Shares Outstanding | 99935714 | 96989200 | 96989200 | 96989200 | 96989200 |
Diluted Shares Outstanding | 99935714 | 96989200 | 96989200 | 96989200 | 96989200 |
Income Statement Trend
Khaitan Chemicals Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 797.0K | 542.0K | 1.6M | 471.9M | 3.4M |
Short-term Investments | 199.0M | 74.8M | 194.7M | 158.5M | 90.4M |
Accounts Receivable | 722.9M | 489.6M | 650.9M | 380.2M | 436.2M |
Inventory | 2.2B | 2.8B | 2.5B | 2.1B | 1.1B |
Other Current Assets | 1.7B | 5.4M | 4.2M | 5.5M | 833.3M |
Total Current Assets | 4.7B | 4.8B | 5.6B | 4.5B | 2.5B |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.3B | 129.1M | 119.9M | 95.7M | 23.9M |
Goodwill | 1.9M | 447.0K | 0 | 0 | 108.0K |
Intangible Assets | - | 447.0K | - | - | 108.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | -886.0K | 943.0K | 1.0K | 1.0K | -1.0K |
Total Non-Current Assets | 1.4B | 1.4B | 1.5B | 1.2B | 1.1B |
Total Assets | 6.2B | 6.2B | 7.1B | 5.7B | 3.5B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 419.6M | 522.3M | 1.2B | 988.7M | 476.8M |
Short-term Debt | 2.8B | 2.9B | 2.0B | 1.3B | 595.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 249.3M | 130.0M | 284.5M | 501.8M | 209.9M |
Total Current Liabilities | 3.6B | 3.7B | 3.7B | 2.9B | 1.4B |
Non-Current Liabilities | |||||
Long-term Debt | 356.1M | 219.3M | 298.4M | 127.8M | 195.5M |
Deferred Tax Liabilities | 0 | 101.9M | 102.6M | 115.4M | 147.8M |
Other Non-Current Liabilities | 30.0K | - | - | - | - |
Total Non-Current Liabilities | 379.1M | 329.8M | 410.0M | 252.9M | 361.6M |
Total Liabilities | 4.0B | 4.0B | 4.1B | 3.2B | 1.8B |
Equity | |||||
Common Stock | 97.0M | 97.0M | 97.0M | 97.0M | 97.0M |
Retained Earnings | - | 1.4B | 2.2B | 1.7B | 983.7M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.2B | 2.2B | 2.9B | 2.5B | 1.7B |
Key Metrics | |||||
Total Debt | 3.2B | 3.2B | 2.3B | 1.4B | 790.5M |
Working Capital | 1.2B | 1.1B | 1.9B | 1.5B | 1.0B |
Balance Sheet Composition
Khaitan Chemicals Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -165.0M | -718.6M | 574.0M | 1.0B | 385.7M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 319.8M | 515.2M | -1.8B | -1.2B | 349.6M |
Operating Cash Flow | 446.1M | 102.9M | -1.1B | -76.2M | 866.0M |
Investing Activities | |||||
Capital Expenditures | -47.9M | -118.6M | -196.2M | -134.8M | -52.0M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -172.9M | 7.3M | -230.3M | -203.8M | -61.2M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | -28.9M | -14.6M | -29.1M | -28.9M |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | -119.3M | -128.3M |
Financing Cash Flow | -106.2M | 925.9M | 668.8M | 542.0M | -632.2M |
Free Cash Flow | 393.4M | -672.6M | -1.2B | 122.1M | 791.4M |
Net Change in Cash | 167.1M | 1.0B | -616.3M | 261.9M | 172.6M |
Cash Flow Trend
Khaitan Chemicals Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
26.17
Price to Book
4.64
Price to Sales
1.43
PEG Ratio
-0.11
Profitability Ratios
Profit Margin
0.19%
Operating Margin
6.03%
Return on Equity
0.63%
Return on Assets
1.40%
Financial Health
Current Ratio
1.32
Debt to Equity
142.83
Beta
0.11
Per Share Data
EPS (TTM)
₹4.07
Book Value per Share
₹22.96
Revenue per Share
₹74.25
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
khaichem | 10.3B | 26.17 | 4.64 | 0.63% | 0.19% | 142.83 |
Coromandel | 667.4B | 29.56 | 6.01 | 18.41% | 8.56% | 6.95 |
UPL | 622.8B | 3.00 | 1.63 | 2.01% | 0.09% | 105.06 |
National Fertilizers | 46.5B | 30.27 | 1.71 | 6.77% | 0.84% | 73.68 |
Bharat Rasayan | 42.4B | 30.83 | 3.75 | 12.47% | 10.84% | 7.54 |
Mangalore Chemicals | 42.1B | 26.06 | 3.96 | 13.50% | 4.78% | 69.63 |
Financial data is updated regularly. All figures are in the company's reporting currency.